{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:57:37Z","timestamp":1783238257010,"version":"3.54.6"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:00:00Z","timestamp":1608422400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development.<\/jats:p>","DOI":"10.1186\/s12929-020-00695-2","type":"journal-article","created":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T03:03:14Z","timestamp":1608433394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":339,"title":["Coronavirus vaccine development: from SARS and MERS to COVID-19"],"prefix":"10.1186","volume":"27","author":[{"given":"Yen-Der","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Han","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ferrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Fu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-4584","authenticated-orcid":false,"given":"T.-C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,20]]},"reference":[{"key":"695_CR1","unstructured":"Centers-for-Disease-Control-and-Prevention. Human Coronavirus Types. 2020.\u00a0https:\/\/www.cdc.gov\/coronavirus\/types.html."},{"issue":"4 Pt B","key":"695_CR2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/135965350701200S01.1","volume":"12","author":"L van der Hoek","year":"2007","unstructured":"van der Hoek L. Human coronaviruses: what do they cause? Antivir Ther. 2007;12(4 Pt B):651\u20138.","journal-title":"Antivir Ther"},{"key":"695_CR3","volume-title":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003","author":"World-Health-Organization","year":"2003","unstructured":"World-Health-Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Geneva: World-Health-Organization; 2003."},{"key":"695_CR4","volume-title":"MERS situation update, January 2020","author":"World-Health-Organization","year":"2020","unstructured":"World-Health-Organization. MERS situation update, January 2020. Geneva: World-Health-Organization; 2020a."},{"key":"695_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.19719","author":"C Del Rio","year":"2020","unstructured":"Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.19719.","journal-title":"JAMA"},{"issue":"13","key":"695_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199\u2013207.","journal-title":"N Engl J Med"},{"issue":"22","key":"695_CR7","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1056\/NEJMe2009758","volume":"382","author":"M Gandhi","year":"2020","unstructured":"Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles\u2019 Heel of current strategies to control covid-19. N Engl J Med. 2020;382(22):2158\u201360.","journal-title":"N Engl J Med"},{"key":"695_CR8","volume-title":"Coronavirus disease (COVID-19) pandemic","author":"World-Health-Organization","year":"2020","unstructured":"World-Health-Organization. Coronavirus disease (COVID-19) pandemic. Geneva: World-Health-Organization; 2020b."},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","volume":"66","author":"PS Masters","year":"2006","unstructured":"Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193\u2013292.","journal-title":"Adv Virus Res"},{"issue":"3","key":"695_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrmicro775","volume":"1","author":"K Stadler","year":"2003","unstructured":"Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R. SARS\u2013beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209\u201318.","journal-title":"Nat Rev Microbiol"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","volume":"96","author":"L Enjuanes","year":"2016","unstructured":"Enjuanes L, Zuniga S, Castano-Rodriguez C, Gutierrez-Alvarez J, Canton J, Sola I. Molecular Basis of Coronavirus Virulence and Vaccine Development. Adv Virus Res. 2016;96:245\u201386.","journal-title":"Adv Virus Res"},{"key":"695_CR12","unstructured":"NCBI-Reference-Sequence. SARS coronavirus Tor2, complete genome. 2020."},{"key":"695_CR13","unstructured":"NCBI-Reference-Sequence. Middle East respiratory syndrome-related coronavirus isolate HCoV-EMC\/2012, complete genome. 2020."},{"key":"695_CR14","unstructured":"NCBI-Reference-Sequence. Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. 2020."},{"issue":"3","key":"695_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226\u201336.","journal-title":"Nat Rev Microbiol"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.","journal-title":"Front Microbiol"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","volume":"96","author":"EJ Snijder","year":"2016","unstructured":"Snijder EJ, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 2016;96:59\u2013126.","journal-title":"Adv Virus Res"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/1743-422X-7-299","volume":"7","author":"Z Cao","year":"2010","unstructured":"Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010;7:299.","journal-title":"Virol J"},{"issue":"6","key":"695_CR19","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1128\/JVI.79.6.3401-3408.2005","volume":"79","author":"X Zhong","year":"2005","unstructured":"Zhong X, Yang H, Guo ZF, Sin WY, Chen W, Xu J, Fu L, Wu J, Mak CK, Cheng CS, Yang Y, Cao S, Wong TY, Lai ST, Xie Y, Guo Z. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol. 2005;79(6):3401\u20138.","journal-title":"J Virol"},{"issue":"5\u20136","key":"695_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.micinf.2005.02.006","volume":"7","author":"M Qiu","year":"2005","unstructured":"Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R, Zhou D, Dai E, Wang X, Si B, Song Y, Li J, Yang L, Wang J, Wang H, Pang X, Zhai J, Du Z, Liu Y, Zhang Y, Li L, Wang J, Sun B, Yang R. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 2005;7(5\u20136):882\u20139.","journal-title":"Microbes Infect"},{"issue":"19","key":"695_CR21","doi-asserted-by":"publisher","first-page":"E2018","DOI":"10.1073\/pnas.1402074111","volume":"111","author":"XC Tang","year":"2014","unstructured":"Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA. 2014;111(19):E2018-2026.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"695_CR22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/cr.2015.113","volume":"25","author":"Y Li","year":"2015","unstructured":"Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, Zhang B, Yuen KY, Perlman S, Gao GF, Yan J. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 2015;25(11):1237\u201349.","journal-title":"Cell Res"},{"issue":"2","key":"695_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1089\/vim.2012.0076","volume":"26","author":"J Li","year":"2013","unstructured":"Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol. 2013;26(2):126\u201332.","journal-title":"Viral Immunol"},{"issue":"12","key":"695_CR24","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1128\/JVI.00083-06","volume":"80","author":"Y He","year":"2006","unstructured":"He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006;80(12):5757\u201367.","journal-title":"J Virol"},{"key":"695_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01651-16","author":"W Tai","year":"2017","unstructured":"Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol. 2017. https:\/\/doi.org\/10.1128\/JVI.01651-16.","journal-title":"J Virol"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","volume":"499","author":"W Tai","year":"2016","unstructured":"Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, Tseng CK, Li F, Jiang S, Du L, Zhou Y. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375\u201382.","journal-title":"Virology"},{"issue":"7","key":"695_CR27","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/21645515.2017.1296994","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang Y, Tai W, Yang J, Zhao G, Sun S, Tseng CK, Jiang S, Zhou Y, Du L, Gao J. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017;13(7):1615\u201324.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"695_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","volume":"44","author":"J Zhao","year":"2016","unstructured":"Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44(6):1379\u201391.","journal-title":"Immunity"},{"issue":"8","key":"695_CR29","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1128\/JCM.43.8.3718-3726.2005","volume":"43","author":"Y He","year":"2005","unstructured":"He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005;43(8):3718\u201326.","journal-title":"J Clin Microbiol"},{"issue":"26","key":"695_CR30","doi-asserted-by":"publisher","first-page":"9804","DOI":"10.1073\/pnas.0403492101","volume":"101","author":"UJ Buchholz","year":"2004","unstructured":"Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 2004;101(26):9804\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"695_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","volume":"27","author":"W Huisman","year":"2009","unstructured":"Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine. 2009;27(4):505\u201312.","journal-title":"Vaccine"},{"issue":"4","key":"695_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"YW Kam","year":"2007","unstructured":"Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, Subbarao K, Peiris M, Nal B, Altmeyer R. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729\u201340.","journal-title":"Vaccine"},{"issue":"20","key":"695_CR33","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1128\/JVI.00671-11","volume":"85","author":"M Jaume","year":"2011","unstructured":"Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daeron M, Bruzzone R, Peiris JS. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Virol. 2011;85(20):10582\u201397.","journal-title":"J Virol"},{"issue":"2","key":"695_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","volume":"451","author":"SF Wang","year":"2014","unstructured":"Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YM, Huang JC. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208\u201314.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"695_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1128\/CVI.00152-06","volume":"13","author":"KS Rosenthal","year":"2006","unstructured":"Rosenthal KS, Zimmerman DH. Vaccines: all things considered. Clin Vaccine Immunol. 2006;13(8):821\u20139.","journal-title":"Clin Vaccine Immunol"},{"issue":"23","key":"695_CR36","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201\u201315.","journal-title":"J Virol"},{"issue":"4","key":"695_CR37","doi-asserted-by":"publisher","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7(4):e35421.","journal-title":"PLoS ONE"},{"issue":"15","key":"695_CR38","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1128\/JVI.00983-14","volume":"88","author":"N Iwata-Yoshikawa","year":"2014","unstructured":"Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014;88(15):8597\u2013614.","journal-title":"J Virol"},{"issue":"6","key":"695_CR39","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995\u20133007.","journal-title":"J Virol"},{"issue":"2","key":"695_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","volume":"324","author":"Y He","year":"2004","unstructured":"He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773\u201381.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"695_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbrc.2009.05.003","volume":"384","author":"L Du","year":"2009","unstructured":"Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009;384(4):486\u201390.","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"695_CR42","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","volume":"25","author":"L Du","year":"2007","unstructured":"Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"695_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","volume":"393","author":"L Du","year":"2009","unstructured":"Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009;393(1):144\u201350.","journal-title":"Virology"},{"issue":"2","key":"695_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/vim.2009.0090","volume":"23","author":"L Du","year":"2010","unstructured":"Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010;23(2):211\u20139.","journal-title":"Viral Immunol"},{"issue":"8","key":"695_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1089\/dna.2005.24.510","volume":"24","author":"Y Guo","year":"2005","unstructured":"Guo Y, Sun S, Wang K, Zhang S, Zhu W, Chen Z. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 2005;24(8):510\u20135.","journal-title":"DNA Cell Biol"},{"issue":"16","key":"695_CR46","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","volume":"24","author":"SJ Liu","year":"2006","unstructured":"Liu SJ, Leng CH, Lien SP, Chi HY, Huang CY, Lin CL, Lian WC, Chen CJ, Hsieh SL, Chong P. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine. 2006;24(16):3100\u20138.","journal-title":"Vaccine"},{"key":"695_CR47","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1038\/ncomms8712","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.","journal-title":"Nat Commun"},{"issue":"3","key":"695_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/v11030212","volume":"11","author":"DR Adney","year":"2019","unstructured":"Adney DR, Wang L, van Doremalen N, Shi W, Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, Modjarrad K, Petrovsky N, Graham BS, Bowen RA, Munster VJ. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11(3):212.","journal-title":"Viruses"},{"issue":"1","key":"695_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vaccine.2016.11.064","volume":"35","author":"L Jiaming","year":"2017","unstructured":"Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, Jinghua Y, Gao GF, Chuan Q, Wenjie T. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10\u20138.","journal-title":"Vaccine"},{"issue":"2","key":"695_CR50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/cmi.2015.03","volume":"13","author":"N Zhang","year":"2016","unstructured":"Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13(2):180\u201390.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"695_CR51","doi-asserted-by":"publisher","first-page":"e112602","DOI":"10.1371\/journal.pone.0112602","volume":"9","author":"J Lan","year":"2014","unstructured":"Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, Lu Z, Gao GF, Tan W. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE. 2014;9(11):e112602.","journal-title":"PLoS ONE"},{"issue":"1","key":"695_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/vaccines8010139","volume":"8","author":"C Qian","year":"2020","unstructured":"Qian C, Liu X, Xu Q, Wang Z, Chen J, Li T, Zheng Q, Yu H, Gu Y, Li S, Xia N. Recent progress on the versatility of virus-like particles. Vaccines (Basel). 2020;8(1):139.","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"695_CR53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.vaccine.2007.11.092","volume":"26","author":"KG Lokugamage","year":"2008","unstructured":"Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, Newman P, Kent Tseng CT, Peters CJ, Makino S. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine. 2008;26(6):797\u2013808.","journal-title":"Vaccine"},{"issue":"38","key":"695_CR54","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","volume":"29","author":"YV Liu","year":"2011","unstructured":"Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 2011;29(38):6606\u201313.","journal-title":"Vaccine"},{"issue":"8","key":"695_CR55","doi-asserted-by":"publisher","first-page":"12686","DOI":"10.18632\/oncotarget.8475","volume":"8","author":"C Wang","year":"2017","unstructured":"Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, Wang T, Gao Y, Yang S, Xia X. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 2017;8(8):12686\u201394.","journal-title":"Oncotarget"},{"key":"695_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","volume":"140","author":"C Wang","year":"2017","unstructured":"Wang C, Zheng X, Gai W, Wong G, Wang H, Jin H, Feng N, Zhao Y, Zhang W, Li N, Zhao G, Li J, Yan J, Gao Y, Hu G, Yang S, Xia X. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 2017;140:55\u201361.","journal-title":"Antiviral Res"},{"key":"695_CR57","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.","journal-title":"Front Immunol"},{"issue":"8","key":"695_CR58","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.gt.3302213","volume":"11","author":"Z Wang","year":"2004","unstructured":"Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, Follmer TT, Rizzuto G, Ciliberto G, Fattori E, Monica NL, Manam S, Ledwith BJ. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004;11(8):711\u201321.","journal-title":"Gene Ther"},{"issue":"2","key":"695_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4161\/hv.2.2.2620","volume":"2","author":"JA Schalk","year":"2006","unstructured":"Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgonne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin. 2006;2(2):45\u201353.","journal-title":"Hum Vaccin"},{"issue":"6982","key":"695_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature02463","volume":"428","author":"ZY Yang","year":"2004","unstructured":"Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561\u20134.","journal-title":"Nature"},{"issue":"9","key":"695_CR61","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","volume":"78","author":"TW Kim","year":"2004","unstructured":"Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DA, Wu TC. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(9):4638\u201345.","journal-title":"J Virol"},{"issue":"1","key":"695_CR62","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.virol.2004.10.016","volume":"331","author":"P Zhao","year":"2005","unstructured":"Zhao P, Cao J, Zhao LJ, Qin ZL, Ke JS, Pan W, Ren H, Yu JG, Qi ZT. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005;331(1):128\u201335.","journal-title":"Virology"},{"issue":"16","key":"695_CR63","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1016\/j.vaccine.2007.01.032","volume":"25","author":"M Okada","year":"2007","unstructured":"Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, Tsunai Y, Inoue R, Nakatani H, Fukamizu R, Namie Y, Yamada J, Takao K, Asai R, Asaki R, Kase T, Takemoto Y, Yoshida S, Peiris JS, Chen PJ, Yamamoto N, Nomura T, Ishida I, Morikawa S, Tashiro M, Sakatani M. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL\/hu mouse models. Vaccine. 2007;25(16):3038\u201340.","journal-title":"Vaccine"},{"issue":"1","key":"695_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbrc.2004.11.147","volume":"327","author":"Z Wang","year":"2005","unstructured":"Wang Z, Yuan Z, Matsumoto M, Hengge UR, Chang YF. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB\/c mice. Biochem Biophys Res Commun. 2005;327(1):130\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"50","key":"695_CR65","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"JE Martin","year":"2008","unstructured":"Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS, Team VRCS. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26(50):6338\u201343.","journal-title":"Vaccine"},{"issue":"35","key":"695_CR66","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1016\/j.vaccine.2005.04.011","volume":"23","author":"AN Zakhartchouk","year":"2005","unstructured":"Zakhartchouk AN, Liu Q, Petric M, Babiuk LA. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine. 2005;23(35):4385\u201391.","journal-title":"Vaccine"},{"issue":"42","key":"695_CR67","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1016\/j.vaccine.2005.05.023","volume":"23","author":"PC Woo","year":"2005","unstructured":"Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005;23(42):4959\u201368.","journal-title":"Vaccine"},{"issue":"301","key":"695_CR68","doi-asserted-by":"publisher","first-page":"301ra132","DOI":"10.1126\/scitranslmed.aac7462","volume":"7","author":"K Muthumani","year":"2015","unstructured":"Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DB. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132.","journal-title":"Sci Transl Med"},{"issue":"9","key":"695_CR69","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013\u201322.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"695_CR70","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, Xu Z, Walters J, Bhojnagarwala P, Yang M, Chokkalingam N, Pezzoli P, Parzych E, Reuschel EL, Doan A, Tursi N, Vasquez M, Choi J, Tello-Ruiz E, Maricic I, Bah MA, Wu Y, Amante D, Park DH, Dia Y, Ali AR, Zaidi FI, Generotti A, Kim KY, Herring TA, Reeder S, Andrade VM, Buttigieg K, Zhao G, Wu JM, Li D, Bao L, Liu J, Deng W, Qin C, Brown AS, Khoshnejad M, Wang N, Chu J, Wrapp D, McLellan JS, Muthumani K, Wang B, Carroll MW, Kim JJ, Boyer J, Kulp DW, Humeau L, Weiner DB, Broderick KE. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.","journal-title":"Nat Commun"},{"key":"695_CR71","doi-asserted-by":"publisher","first-page":"44875","DOI":"10.1038\/srep44875","volume":"7","author":"SS Al-Amri","year":"2017","unstructured":"Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, Alhabbab RY, Azhar EI, Li X, Hashem AM. Immunogenicity of Candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep. 2017;7:44875.","journal-title":"Sci Rep"},{"issue":"10","key":"695_CR72","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.4161\/hv.29594","volume":"10","author":"H Fausther-Bovendo","year":"2014","unstructured":"Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important? Hum Vaccin Immunother. 2014;10(10):2875\u201384.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"695_CR73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4161\/hv.23241","volume":"9","author":"MC Knuchel","year":"2013","unstructured":"Knuchel MC, Marty RR, Morin TN, Ilter O, Zuniga A, Naim HY. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vacc Immunother. 2013;9(3):599\u2013606.","journal-title":"Hum Vacc Immunother"},{"issue":"1","key":"695_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.virusres.2007.01.021","volume":"133","author":"L Enjuanes","year":"2008","unstructured":"Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008;133(1):45\u201362.","journal-title":"Virus Res"},{"issue":"1","key":"695_CR75","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/v11010074","volume":"11","author":"C Schindewolf","year":"2019","unstructured":"Schindewolf C, Menachery VD. Middle East respiratory syndrome vaccine candidates: cautious optimism. Viruses. 2019;11(1):74.","journal-title":"Viruses"},{"issue":"9399","key":"695_CR76","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","volume":"362","author":"W Gao","year":"2003","unstructured":"Gao W, Tamin A, Soloff A, D\u2019Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362(9399):1895\u20136.","journal-title":"Lancet"},{"issue":"1\u20132","key":"695_CR77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.virusres.2005.02.009","volume":"112","author":"RY Liu","year":"2005","unstructured":"Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang YL, Ke ML, Wang JM, Tan WP, Zhang RH, Chen HK, Zeng YX, Huang W. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 2005;112(1\u20132):24\u201331.","journal-title":"Virus Res"},{"issue":"Pt 9","key":"695_CR78","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1099\/vir.0.2008\/001891-0","volume":"89","author":"RH See","year":"2008","unstructured":"See RH, Petric M, Lawrence DJ, Mok CPY, Rowe T, Zitzow LA, Karunakaran KP, Voss TG, Brunham RC, Gauldie J, Finlay BB, Roper RL. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol. 2008;89(Pt 9):2136\u201346.","journal-title":"J Gen Virol"},{"issue":"28","key":"695_CR79","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1016\/j.vaccine.2007.04.065","volume":"25","author":"GP Kobinger","year":"2007","unstructured":"Kobinger GP, Figueredo JM, Rowe T, Zhi Y, Gao G, Sanmiguel JC, Bell P, Wivel NA, Zitzow LA, Flieder DB, Hogan RJ, Wilson JM. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine. 2007;25(28):5220\u201331.","journal-title":"Vaccine"},{"key":"695_CR80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz A, Sutter G. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res. 2017;97:187\u2013243.","journal-title":"Adv Virus Res"},{"issue":"17","key":"695_CR81","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.1073\/pnas.0401939101","volume":"101","author":"H Bisht","year":"2004","unstructured":"Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA. 2004;101(17):6641\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"695_CR82","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","volume":"79","author":"Z Chen","year":"2005","unstructured":"Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79(5):2678\u201388.","journal-title":"J Virol"},{"issue":"17\u201318","key":"695_CR83","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","volume":"23","author":"M Czub","year":"2005","unstructured":"Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17\u201318):2273\u20139.","journal-title":"Vaccine"},{"issue":"22","key":"695_CR84","doi-asserted-by":"publisher","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","volume":"78","author":"H Weingartl","year":"2004","unstructured":"Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672\u20136.","journal-title":"J Virol"},{"issue":"12","key":"695_CR85","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1371\/journal.pmed.0030525","volume":"3","author":"D Deming","year":"2006","unstructured":"Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3(12):e525.","journal-title":"PLoS Med"},{"issue":"1","key":"695_CR86","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1128\/JVI.01805-10","volume":"85","author":"T Sheahan","year":"2011","unstructured":"Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol. 2011;85(1):217\u201330.","journal-title":"J Virol"},{"issue":"9427","key":"695_CR87","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","volume":"363","author":"A Bukreyev","year":"2004","unstructured":"Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363(9427):2122\u20137.","journal-title":"Lancet"},{"issue":"2","key":"695_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.virol.2005.06.016","volume":"340","author":"SU Kapadia","year":"2005","unstructured":"Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology. 2005;340(2):174\u201382.","journal-title":"Virology"},{"issue":"45","key":"695_CR89","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","volume":"32","author":"E Kim","year":"2014","unstructured":"Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB\/c mice. Vaccine. 2014;32(45):5975\u201382.","journal-title":"Vaccine"},{"issue":"4","key":"695_CR90","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/imm.12462","volume":"145","author":"X Guo","year":"2015","unstructured":"Guo X, Deng Y, Chen H, Lan J, Wang W, Zou X, Hung T, Lu Z, Tan W. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145(4):476\u201384.","journal-title":"Immunology"},{"issue":"24","key":"695_CR91","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1016\/j.vaccine.2018.04.082","volume":"36","author":"SY Jung","year":"2018","unstructured":"Jung SY, Kang KW, Lee EY, Seo DW, Kim HL, Kim H, Kwon T, Park HL, Kim H, Lee SM, Nam JH. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36(24):3468\u201376.","journal-title":"Vaccine"},{"issue":"10240","key":"695_CR92","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845\u201354.","journal-title":"Lancet"},{"issue":"10249","key":"695_CR93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479\u201388.","journal-title":"Lancet"},{"issue":"30","key":"695_CR94","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","volume":"35","author":"NK Alharbi","year":"2017","unstructured":"Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35(30):3780\u20138.","journal-title":"Vaccine"},{"key":"695_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","volume":"2","author":"VJ Munster","year":"2017","unstructured":"Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, van Doremalen N, Gilbert SC, de Wit E, Warimwe GM. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2:28.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"695_CR96","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1038\/s41598-019-52730-4","volume":"9","author":"NK Alharbi","year":"2019","unstructured":"Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, Aldubaib M, Almansour A, Temperton NJ, Kupke A, Becker S, Abu-Obaidah A, Alkarar A, Yoon IK, Azhar E, Lambe T, Bayoumi F, Aldowerij A, Ibrahim OH, Gilbert SC, Balkhy HH. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep. 2019;9(1):16292.","journal-title":"Sci Rep"},{"issue":"24","key":"695_CR97","doi-asserted-by":"publisher","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","volume":"6","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T, Fischer RJ, Okumura A, Hanley PW, Saturday G, Edwards NJ, Clark MHA, Lambe T, Gilbert SC, Munster VJ. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci Adv. 2020;6(24):eaba8399.","journal-title":"Sci Adv"},{"issue":"7","key":"695_CR98","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","volume":"20","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, Halwe S, Jeong Y, Park YS, Kim JO, Song M, Boyd A, Tran N, Silman D, Poulton I, Datoo M, Marshall J, Themistocleous Y, Lawrie A, Roberts R, Berrie E, Becker S, Lambe T, Hill A, Ewer K, Gilbert S. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020;20(7):816\u201326.","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"695_CR99","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford CVTG. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467\u201378.","journal-title":"Lancet"},{"issue":"16","key":"695_CR100","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1128\/JVI.00614-15","volume":"89","author":"A Volz","year":"2015","unstructured":"Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651\u20136.","journal-title":"J Virol"},{"issue":"6268","key":"695_CR101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.aad1283","volume":"351","author":"BL Haagmans","year":"2016","unstructured":"Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, Bensaid A, Solanes Foz D, Kuiken T, Baumgartner W, Segales J, Sutter G, Osterhaus AD. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77\u201381.","journal-title":"Science"},{"key":"695_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30248-6","author":"T Koch","year":"2020","unstructured":"Koch T, Dahlke C, Fathi A, Kupke A, Krahling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30248-6.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"695_CR103","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/jit609","volume":"209","author":"S Agnihothram","year":"2014","unstructured":"Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014;209(7):995\u20131006.","journal-title":"J Infect Dis"},{"issue":"22","key":"695_CR104","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1128\/JVI.01815-15","volume":"89","author":"AH Malczyk","year":"2015","unstructured":"Malczyk AH, Kupke A, Prufer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Suzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Muhlebach MD. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol. 2015;89(22):11654\u201367.","journal-title":"J Virol"},{"issue":"2","key":"695_CR105","doi-asserted-by":"publisher","first-page":"e02040-16","DOI":"10.1128\/JVI.02040-16","volume":"91","author":"C Wirblich","year":"2017","unstructured":"Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 2017;91(2):e02040-16.","journal-title":"J Virol"},{"issue":"10","key":"695_CR106","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S2095-3119(17)61660-5","volume":"16","author":"RQ Liu","year":"2017","unstructured":"Liu RQ, Ge JY, Wang JL, Shao Y, Zhang HL, Wang JL, Wen ZY, Bu ZG. Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J Integr Agric. 2017;16(10):2264\u201373.","journal-title":"J Integr Agric"},{"key":"695_CR107","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","volume":"150","author":"R Liu","year":"2018","unstructured":"Liu R, Wang J, Shao Y, Wang X, Zhang H, Shuai L, Ge J, Wen Z, Bu Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 2018;150:30\u20138.","journal-title":"Antiviral Res"},{"issue":"10","key":"695_CR108","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/intimm\/dxh143","volume":"16","author":"N Takasuka","year":"2004","unstructured":"Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S, Odagiri T, Tashiro M, Yoshikura H, Takemori T, Tsunetsugu-Yokota Y. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423\u201330.","journal-title":"Int Immunol"},{"issue":"7","key":"695_CR109","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.vaccine.2004.07.031","volume":"23","author":"D Qu","year":"2005","unstructured":"Qu D, Zheng B, Yao X, Guan Y, Yuan ZH, Zhong NS, Lu LW, Xie JP, Wen YM. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine. 2005;23(7):924\u201331.","journal-title":"Vaccine"},{"issue":"7","key":"695_CR110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","volume":"12","author":"JT Lin","year":"2007","unstructured":"Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, Chen X, Liu YX, Gao H, Jia YP, Liu Y, Sun RH, Wang X, Yu DZ, Hai R, Gao Q, Ning Y, Wang HX, Li MC, Kan B, Dong GM, An Q, Wang YQ, Han J, Qin C, Yin WD, Dongs XP. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107\u201313.","journal-title":"Antivir Ther"},{"issue":"9","key":"695_CR111","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, Couch RB, Tseng CT. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351\u20136.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"695_CR112","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41426-018-0056-7","volume":"7","author":"Y Deng","year":"2018","unstructured":"Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018;7(1):60.","journal-title":"Emerg Microbes Infect"},{"key":"695_CR113","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","volume":"479\u2013480","author":"PD Minor","year":"2015","unstructured":"Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479\u2013480:379\u201392.","journal-title":"Virology"},{"issue":"15","key":"695_CR114","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1128\/JVI.00304-08","volume":"82","author":"EW Lamirande","year":"2008","unstructured":"Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008;82(15):7721\u20134.","journal-title":"J Virol"},{"issue":"17","key":"695_CR115","doi-asserted-by":"publisher","first-page":"e00710","DOI":"10.1128\/JVI.00710-18","volume":"92","author":"VD Menachery","year":"2018","unstructured":"Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH 3rd, Leist SR, Yount BL Jr, McAnarney ET, Graham RL, Waters KM, Baric RS. Combination attenuation offers strategy for live attenuated coronavirus vaccines. J Virol. 2018;92(17):e00710-e718.","journal-title":"J Virol"},{"issue":"6","key":"695_CR116","doi-asserted-by":"publisher","first-page":"e00346-17","DOI":"10.1128\/mSphere.00346-17","volume":"2","author":"VD Menachery","year":"2017","unstructured":"Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH 3rd, Leist SR, Yount BL Jr, Graham RL, McAnarney ET, Stratton KG, Cockrell AS, Debbink K, Sims AC, Waters KM, Baric RS. Middle East Respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere. 2017;2(6):e00346-17.","journal-title":"mSphere"},{"issue":"12","key":"695_CR117","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/nm.2972","volume":"18","author":"RL Graham","year":"2012","unstructured":"Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med. 2012;18(12):1820\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"695_CR118","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"D Schoeman","year":"2019","unstructured":"Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69.","journal-title":"Virol J"},{"key":"695_CR119","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2014.07.024","volume":"194","author":"ML DeDiego","year":"2014","unstructured":"DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, Regla-Nava JA, Castano-Rodriguez C, Fernandez-Delgado R, Usera F, Enjuanes L. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus Res. 2014;194:124\u201337.","journal-title":"Virus Res"},{"key":"695_CR120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.virusres.2014.09.009","volume":"194","author":"VD Menachery","year":"2014","unstructured":"Menachery VD, Debbink K, Baric RS. Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments. Virus Res. 2014;194:191\u20139.","journal-title":"Virus Res"},{"issue":"5","key":"695_CR121","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","volume":"79","author":"F Robson","year":"2020","unstructured":"Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79(5):710\u201327.","journal-title":"Mol Cell"},{"issue":"8","key":"695_CR122","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810\u20132.","journal-title":"Nat Mater"},{"issue":"21","key":"695_CR123","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969\u201373.","journal-title":"N Engl J Med"},{"key":"695_CR124","unstructured":"Johnson-&-Johnson. Johnson & Johnson announces a lead vaccine candidate for COVID-19; landmark new partnership with U.S. Department of Health & Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use. 2020."},{"key":"695_CR125","unstructured":"GSK. GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations. 2020."},{"key":"695_CR126","unstructured":"Chemical-&-Engineering-News. Moderna picks Lonza to make 1 billion doses of its coronavirus vaccine. 2020."},{"key":"695_CR127","unstructured":"CNN-Health. US taxpayers are funding six Covid vaccines. Here's how they work. 2020."},{"key":"695_CR128","unstructured":"REUTERS. EU to use $2.7 billion fund to buy promising COVID-19 vaccines. 2020."},{"key":"695_CR129","unstructured":"AP-News. China aims to make 1 billion COVID-19 vaccine doses a year. 2020."},{"key":"695_CR130","volume-title":"Draft landscape of COVID-19 candidate vaccines","author":"World-Health-Organization","year":"2020","unstructured":"World-Health-Organization. Draft landscape of COVID-19 candidate vaccines. Geneva: World-Health-Organization; 2020c."},{"key":"695_CR131","unstructured":"Novavax. NVX-CoV2373 COVID-19 Vaccine candidate phase 1\/2, part 1, clinical trial results. 2020."},{"key":"695_CR132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2026920.","journal-title":"N Engl J Med"},{"issue":"3","key":"695_CR133","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C, Yan J, Gao GF. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722-733 e711.","journal-title":"Cell"},{"issue":"10","key":"695_CR134","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.4161\/hv.24702","volume":"9","author":"MC Diehl","year":"2013","unstructured":"Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013;9(10):2246\u201352.","journal-title":"Hum Vaccin Immunother"},{"key":"695_CR135","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.28.225649","author":"A Patel","year":"2020","unstructured":"Patel A, Walters J, Reuschel EL, Schultheis K, Parzych E, Gary EN, Maricic I, Purwar M, Eblimit Z, Walker SN, Guimet D, Bhojnagarwala P, Doan A, Xu Z, Elwood D, Reeder SM, Pessaint L, Kim KY, Cook A, Chokkalingam N, Finneyfrock B, Tello-Ruiz E, Dodson A, Choi J, Generotti A, Harrison J, Tursi NJ, Andrade VM, Dia Y, Zaidi FI, Andersen H, Lewis MG, Muthumani K, Kim JJ, Kulp DW, Humeau LM, Ramos S, Smith TRF, Weiner DB, Broderick KE. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.28.225649.","journal-title":"bioRxiv"},{"key":"695_CR136","unstructured":"INOVIO-Pharmaceuticals. INOVIO announces positive interim phase 1 data for INO-4800 vaccine for COVID-19. 2020.\u00a0http:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2020\/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19\/default.aspx."},{"key":"695_CR137","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","volume":"240","author":"KJ Kauffman","year":"2016","unstructured":"Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release. 2016;240:227\u201334.","journal-title":"J Control Release"},{"issue":"10","key":"695_CR138","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Kariko K, Tureci O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"695_CR139","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"695_CR140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","author":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson 2nd PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, m RNASG","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O\u2019Dell S, Schmidt SD, Swanson 2nd PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, m RNASG. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2022483.","journal-title":"N Engl J Med"},{"key":"695_CR141","doi-asserted-by":"publisher","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson 2nd PA, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH, m RNASG. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2028436.","DOI":"10.1056\/NEJMoa2028436"},{"key":"695_CR142","unstructured":"Moderna\u2019s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study. Moderna, 2020. https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy."},{"key":"695_CR143","unstructured":"Genetic-Engineering-&-Biotechnology-News. BioNTech, Pfizer, and Fosun Pharma\u2014BNT162. Genetic Engineering & Biotechnology News. 2020."},{"key":"695_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Tureci O, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Sahin U, Jansen KU. Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2639-4.","journal-title":"Nature"},{"key":"695_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lorks V, Sikorski J, Hilker R, Becker D, Eller AK, Grutzner J, Boesler C, Rosenbaum C, Kuhnle MC, Luxemburger U, Kemmer-Bruck A, Langer D, Bexon M, Bolte S, Kariko K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Tureci O. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2814-7.","journal-title":"Nature"},{"key":"695_CR146","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2027906","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Tureci O, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Sahin U, Gruber WC. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa2027906.","journal-title":"N Engl J Med"},{"key":"695_CR147","unstructured":"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. Pfizer, 2020. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine."},{"key":"695_CR148","unstructured":"The-New-York-Times. AstraZeneca Pauses Vaccine Trial for Safety Review. 2020."},{"key":"695_CR149","unstructured":"Astrazeneca. COVID-19 vaccine AZD1222 clinical trials resumed in the UK. 2020."},{"key":"695_CR150","unstructured":"AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. Astrazeneca, 2020. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/azd1222hlr.html."},{"issue":"10255","key":"695_CR151","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet. 2020;396(10255):887\u201397.","journal-title":"Lancet"},{"key":"695_CR152","unstructured":"Second Interim Analysis of Clinical Trial Data Showed a 91.4% Efficacy for the Sputnik V Vaccine on Day 28 After the First Dose; Vaccine Efficacy is Over 95% 42 Days After the First Dose. Sputnik V, 2020. https:\/\/sputnikvaccine.com\/newsroom\/pressreleases\/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d\/."},{"issue":"6499","key":"695_CR153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77\u201381.","journal-title":"Science"},{"issue":"10","key":"695_CR154","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951\u201360.","journal-title":"JAMA"},{"issue":"3","key":"695_CR155","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-721 e719.","journal-title":"Cell"},{"key":"695_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30831-8","author":"S Xia","year":"2020","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30831-8.","journal-title":"Lancet Infect Dis"},{"key":"695_CR157","unstructured":"AIVITA-Biomedical. SARS-COV-2 VACCINE. 2020."},{"key":"695_CR158","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41421-020-00197-3","volume":"6","author":"LK Zhou","year":"2020","unstructured":"Zhou LK, Zhou Z, Jiang XM, Zheng Y, Chen X, Fu Z, Xiao G, Zhang CY, Zhang LK, Yi Y. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Discov. 2020;6:54.","journal-title":"Cell Discov"},{"issue":"10","key":"695_CR159","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.vaccine.2004.09.006","volume":"23","author":"LG Stensballe","year":"2005","unstructured":"Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005;23(10):1251\u20137.","journal-title":"Vaccine"},{"issue":"2","key":"695_CR160","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/infdis\/136.2.171","volume":"136","author":"JC Spencer","year":"1977","unstructured":"Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J Infect Dis. 1977;136(2):171\u20135.","journal-title":"J Infect Dis"},{"issue":"1","key":"695_CR161","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3181\/00379727-152-39327","volume":"152","author":"SE Starr","year":"1976","unstructured":"Starr SE, Visintine AM, Tomeh MO, Nahmias AJ. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc Soc Exp Biol Med. 1976;152(1):57\u201360.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"6","key":"695_CR162","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","volume":"20","author":"LAJ O'Neill","year":"2020","unstructured":"O\u2019Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020;20(6):335\u20137.","journal-title":"Nat Rev Immunol"},{"key":"695_CR163","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.20042937","author":"A Miller","year":"2020","unstructured":"Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.24.20042937.","journal-title":"medRxiv"},{"issue":"11","key":"695_CR164","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1056\/NEJMc070348","volume":"357","author":"WC Cao","year":"2007","unstructured":"Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162\u20133.","journal-title":"N Engl J Med"},{"issue":"10","key":"695_CR165","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3201\/eid1310.070576","volume":"13","author":"LP Wu","year":"2007","unstructured":"Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, Zheng L, Lan T, Wang LF, Liang GD. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562\u20134.","journal-title":"Emerg Infect Dis"},{"key":"695_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30783-0","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki A. What reinfections mean for COVID-19. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30783-0.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"695_CR167","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3390\/jcm9072268","volume":"9","author":"JH Ko","year":"2020","unstructured":"Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, Kim CJ, Jeong C, Kim YJ, Shon HJ, Kang ES, Choi YK, Peck KR. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J Clin Med. 2020;9(7):2268.","journal-title":"J Clin Med"},{"issue":"7824","key":"695_CR168","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/d41586-020-02544-6","volume":"585","author":"E Callaway","year":"2020","unstructured":"Callaway E. The coronavirus is mutating\u2014does it matter? Nature. 2020;585(7824):174\u20137.","journal-title":"Nature"},{"issue":"4","key":"695_CR169","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, Sheffield C-GG, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-827 e819.","journal-title":"Cell"},{"key":"695_CR170","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.12.148726","author":"L Zhang","year":"2020","unstructured":"Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.12.148726.","journal-title":"bioRxiv"},{"key":"695_CR171","doi-asserted-by":"publisher","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG. Remdesivir for the treatment of covid-19\u2014final report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2007764","DOI":"10.1056\/NEJMoa2007764"},{"key":"695_CR172","doi-asserted-by":"publisher","unstructured":"Group R.C., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S.N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. Dexamethasone in hospitalized patients with covid-19\u2014preliminary report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","DOI":"10.1056\/NEJMoa2021436"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12929-020-00695-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00695-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T05:46:52Z","timestamp":1670392012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-020-00695-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1186\/s12929-020-00695-2","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr T.C. Wu is a co-founder of and has an equity ownership interest in Papivax LLC. Additionally Dr. Wu owns Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.\u2019s Scientific Advisory Board. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}